Clinical trial
Melphalan and Autologous Stem Cell Transplant Followed By Bortezomib and…
NCT00458822 · Memorial Sloan Kettering Cancer Center, Other · Completed
Key facts
| NCT number | NCT00458822 |
|---|---|
| Title | Melphalan and Autologous Stem Cell Transplant Followed By Bortezomib and Dexamethasone in Treating Patients With Previously Untreated Systemic Amyloidosis |
| Official title | Risk-Adapted Intravenous Melphalan With Stem Cell Transplant and Adjuvant Bortezomib and Dexamethasone for Recently Diagnosed Untreated Patients With Systemic Light-Chain (AL) Amyloidosis |
| Lead sponsor | Memorial Sloan Kettering Cancer Center, Other |
| Collaborators | National Cancer Institute (NCI) NIH |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Multiple Myeloma and Plasma Cell Neoplasm |
| Intervention type | Drug |
| Interventions | bortezomib, dexamethasone |
| Enrollment | 40 |
| Start date | Feb 1, 2007 |
| Primary completion | Mar 1, 2015 |
| Completion | Mar 1, 2015 |
| First posted | Apr 11, 2007 |
| Last update posted | Aug 10, 2016 |
| Countries | United States |
At a glance
- 1–9 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: